http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott Declares 389th Consecutive Quarterly Dividend
-
Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
-
Abbott's (ABT) Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
-
Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
-
Abbott (ABT) Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip Device
-
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
-
Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
-
Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution
-
Abbott (ABT) Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
-
Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner
-
Abbott to Present at J.P. Morgan Healthcare Conference
-
Abbott (ABT) Announces FDA Approves Labeling Update for its HeartMate 3 Heart Pump for use in Pediatric Patients
-
FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients
-
Abbott (ABT) BinaxNOW COVID-19 At-Home Rapid Test Receives FDA EUA
-
Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform
-
Abbott (ABT) Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
-
Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
-
Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health
-
Abbott Increases Quarterly Dividend by 25%
-
Abbott's (ABT) FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
-
Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
-
Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
-
Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
-
Abbott (ABT) Announces the U.S. Launch of the IonicRF Generator for Use in Patients Living With Chronic Pain
-
Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain
-
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device
-
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
-
Absolute Appoints Steven Gatoff as Chief Financial Officer
-
Absolute Declares Quarterly Dividend
-
Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
-
Absolute Unveils Enhanced Global Partner Program
-
Absolute Launches New Mobile App to Enable Customers to Secure At-Risk Endpoints Anytime, Anywhere
-
Abbott (ABT) Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
-
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
-
Abbott (ABT) Releases ID NOW COVID-19 Interim Clinical Study Results from 1,003 People
-
Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
-
Abbott (ABT) FreeStyle Libre 3 System Receives CE Mark
-
Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
-
Abbott (ABT) Receives CE Mark for Next-Generation MitraClip Heart Valve Repair Device to Treat Mitral Regurgitation
-
Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Abbott Declares 387th Consecutive Quarterly Dividend
-
Abbott (ABT) Introduces Libre Sense Glucose Sport Biosensor in Europe
-
Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes
-
New Research from Absolute Underscores Complexities, Gaps in K-12 Device and Data Security Driven by Accelerated Shift to Distance Learning
-
Absolute Accelerates Endpoint Resilience and Operational Agility for Customers in Era of Remote Work and Distance Learning
-
From Target to Twitter, U.S. companies urge workers to vote
-
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

